Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EBITDA: 2020-2024

Historic EBITDA for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$241.6 million.

  • NewAmsterdam Pharma Co N.V's EBITDA fell 330.66% to -$71.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.9 million, marking a year-over-year decrease of 11.03%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.52% down from last year.
  • NewAmsterdam Pharma Co N.V's EBITDA amounted to -$241.6 million in FY2024, which was down 36.52% from -$176.9 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's EBITDA registered a high of -$6,564 during FY2020, and its lowest value of -$241.6 million during FY2024.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's EBITDA had a median value of -$176.9 million in 2023 and averaged -$143.3 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's EBITDA slumped by 632,115.62% in 2021 and then spiked by 72.27% in 2022.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's EBITDA (Yearly) stood at -$6,564 in 2020, then slumped by 632,115.62% to -$41.5 million in 2021, then soared by 72.27% to -$11.5 million in 2022, then tumbled by 1,437.51% to -$176.9 million in 2023, then crashed by 36.52% to -$241.6 million in 2024.